Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Haya Ascher‐Svanum

ResearcherPublications, citations & collaboration network

Haya Ascher‐Svanum is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 233 works, 5,631 citations, an h-index of 43 and an i10-index of 99.

233
Works
5,631
Citations
43
h-index
99
i10-index

How has Haya Ascher‐Svanum's publication output changed over time?

ScholarIQpublication output · 2005–2016

Output grew0% over the shown period — from 1 works in 2005 to 1 in 2016.

1
4
1
1
2
1
1
2005200620072008200920102016

What are the most-cited papers on Haya Ascher‐Svanum?

ScholarIQmost cited works
Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care
Haya Ascher‐Svanum, Douglas E. Faries, Baojin Zhu, Frank R. Ernst, Marvin S. Swartz, Jeff W. Swanson
S17992710. 2006489 Citations
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
R. Conley, Haya Ascher‐Svanum, Baojin Zhu, Douglas E. Faries, BJ Kinon
Schizophrenia Research. 2006296 CitationsOPEN ACCESS
The cost of relapse and the predictors of relapse in the treatment of schizophrenia
Haya Ascher‐Svanum, Baojin Zhu, Douglas E. Faries, David S. Salkever, Eric P. Slade, Xiaomei Peng, Robert R. Conley
BMC Psychiatry. 2010281 CitationsOPEN ACCESS
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Douglas E. Faries, Haya Ascher‐Svanum, Baojin Zhu, Christoph U. Correll, John M. Kane
BMC Psychiatry. 2005183 CitationsOPEN ACCESS
Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia
Bruce J. Kinon, Lei Chen, Haya Ascher‐Svanum, Virginia L. Stauffer, Sara Kollack‐Walker, Wei Zhou, Shitij Kapur, John M. Kane
Neuropsychopharmacology. 2009180 CitationsOPEN ACCESS

Related on ScholarIQ

Eli Lilly (United States)
Institution
Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care
Paper
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
Paper
The cost of relapse and the predictors of relapse in the treatment of schizophrenia
Paper
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Paper
Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia
Paper
470M+ articles · free account